Chromium supplements improve HbA1c, glucose levels in Type 2 diabetics
MedWire News: Study findings suggest that chromium supplementation may help improve glycemic control and lipid levels in patients with new-onset Type 2 diabetes.
"There is growing evidence that chromium may facilitate insulin signaling and chromium supplementation therefore may improve systemic insulin sensitivity," explain Rajendra Agarwal (S.P. Medical College, Bikaner, Rajasthan, India) and team.
To investigate this further, Agarwal and co-researchers recruited 40 patients with Type 2 diabetes to take part in a pilot study. Twenty patients consumed 9 g of brewer's yeast containing 42 µg chromium once a day and 20 consumed 9 g of yeast containing no chromium once a day (placebo) for 3 months.
The participants were asked not to change their diet and living habits during the study.
At 3 months, the researchers found that glycemic control was significantly better in the chromium than the control group.
Serum glucose had decreased by 93.97 mg/dl from baseline in the chromium group versus a smaller reduction of 20.14 mg/dl in the placebo group. Similarly, glycated hemoglobin (HbA1c) decreased by 2.65% versus 0.59% in the placebo group, a significant between-group difference.
Total, low-density lipoprotein cholesterol, and triglycerides were also significantly reduced from baseline in the chromium, but not the control group, by 10.4, 19.61, and 18.93 mg/dl, respectively.
"Thus, this study has demonstrated that chromium supplementation is an effective regimen for newly onset Type-2 diabetic patients and may provide possible positive effect on other coronary risk factors associated," write the authors in the Journal of Trace Elements in Medicine and Biology.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2011
By Helen Albert